29 June 2023: Articles
Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology
Christopher R. Grant A* , Elaine J. Chiao E , Zhaohui L. Arter A , Cary Johnson C , Truc Tran B , Farshid Dayyani E , Krishnansu Tewari E , Valery Vilchez E , Joeseph Carmichael E , May Cho ADOI: 10.12659/AJCR.939448
Am J Case Rep 2023; 24:e939448
Table 1. Immunohistochemical stain and next-generation sequencing for microsatellite instability.
| Specimen | Mismatch repair atatus |
|---|---|
| Tissue immunohistochemistry – primary endometrial carcinoma from uterus | Proficient |
| Caris next-generation sequencing – primary endometrial carcinoma | Quantity not sufficient |
| Tissue immunohistochemistry – recurrent retroperitoneal mass | Deficient |
| Guardant360 biomarker – serum after reoccurrence | Deficient |
| Caris next-generation sequencing – recurrent retroperitoneal mass | Deficient |